tulisokibart

all catalysts(1)

News(10)

• BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
  BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…
  biospace · 2d ago
• Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
  Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’…
  biospace · 3d ago
• #EADV26: Merck shows off mid-stage win for Prometheus drug in skin condition
  Merck detailed some mid-stage data in a debilitating skin condition on Wednesday morning for the centerpiece of its $10.8 billion Prometheus Biosciences acquisition. Both the middle and high doses…
  endpoints · 4d ago
• 6 immunology targets to sustain a mammoth I&I market
  Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
  biospace · 6d ago
• Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
  Analysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.
  biospace · 10d ago
• Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
  Spyre's three-pronged approach to inflammatory bowel disease continues to pay off, with the biotech's anti-IL-23 antibody notching a phase 2 win.
  fiercebiotech · 26d ago
• Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
  The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second qu…
  biospace · 2mo ago
• Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
  The anti-TL1A antibody from Merck's 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside seco…
  biospace · 2mo ago
• J&J pharma leader to retire; Krystal slumps on gene therapy miss
  Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.
  biopharma_dive · 2mo ago
• Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
  A phase 2 trial of Merck & Co.’s anti-TL1A monoclonal antibody has missed its primary endpoint, closing off one avenue for expansion of an asset acquired in a $10.8 billion takeover. The setback wa…
  fiercebiotech · 2mo ago